Alpha 1 adrenoreceptor antagonists

Journal of Clinical Hypertension

Volumn 13, Issue 9, 2011, Pages 654-657

  Grimm Jr , Richard H ^a   Flack, John M ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; CATECHOLAMINE; CHLORTALIDONE; DOXAZOSIN; HYDROCHLOROTHIAZIDE; LISINOPRIL; PRAZOSIN; TERAZOSIN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SELECTIVITY; EXTRACELLULAR FLUID; FOOT EDEMA; HEART FAILURE; HUMAN; HYPERTENSION; LOWER URINARY TRACT SYMPTOM; MICTURITION; PLASMA VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SIDE EFFECT; SODIUM INTAKE; VASOCONSTRICTION; WEIGHT GAIN;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PLASMA VOLUME; TREATMENT OUTCOME;

EID: 80052535765     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00510.x     Document Type: Review

References (12)

1. Neaton JD, Grimm RH, Prineas RJ, et al. Treatment of Mild Hypertension Study: final results. JAMA. 1993;270:713-724.
2. Elmer PJ, Grimm RH, Laing B. Lifestyle intervention: results of the treatment of mild hypertension study (TOMHS). Prev Med. 1995;24:378-388.
3. Wright JT Jr, Harris-Haywood S, Pressel S, et al. Clinical outcomes by race in hypertensive patients with and without metabolic syndrome. Arch Intern Med. 2008;168:207-217.
4. Lithell H, Vessby V. Effect of prazosin on lipoprotein metabolismin premenopausal hypertensive women. J Cardiovasc Pharmacol. 1981;3(Suppl 3):223.
5. Grimm RH, Flack J, Grandits GA. Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA. 1996;275:1549-1556.
6. Pool JL, Lenz ML, Taylor AA. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations. J Hum Hypertens. 1990;4(Suppl 3):23-33.
7. ALLHAT Officers and Coordinators for the ALLHAT Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967-1975.
8. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Diuretic Versus alpha-Blocker as First-line Antihypertensive Therapy: Final Results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246.
9. Einhorn PT, Davis BR, Cushman WC, et al. The antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT) heart failure validation study: diagnosis and prognosis. Am Heart J. 2007;153:42-53.
10. Davis BR, Kostis JB, Simpson LM, et al. Heart failure with preserved and reduced left ventricular ejection fraction in antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation. 2008;118(22):225E-267E.
11. Grimm RH, Davis BR, Piller LB, et al. Heart failure in ALLHAT: did blood pressure medication at study entry influence outcome? J Clin Hypertens (Greenwich). 2009;11:466-474.
12. Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT Study. J Clin Hypertens. 2004;6(3):116-125.